Metazocine is in Schedule II of the Controlled Substances Act 1970 of the United States as a Narcotic with ACSCN 9240 with a 19 gram aggregate manufacturing quota as of 2014. The free base conversion ratio for salts includes 0.81 for the hydrochloride and 0.74 for the hydrobromide.[8] It is listed under the Single Convention for the Control of Narcotic Substances 1961 and is controlled in most countries in the same fashion as is morphine.
^Hori M, Ban M, Imai E, Iwata N, Suzuki Y, Baba Y, Morita T, Fujimura H, Nozaki M, Niwa M (November 1985). "Novel nonnarcotic analgesics with an improved therapeutic ratio. Structure-activity relationships of 8-(methylthio)- and 8-(acylthio)-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines". Journal of Medicinal Chemistry. 28 (11): 1656–61. doi:10.1021/jm00149a020. PMID2999399.
^Berzetei-Gurske I, Loew GH (1990). "The novel antagonist profile of (-)metazocine". Progress in Clinical and Biological Research. 328: 33–6. PMID2154788.
^Shannon HE (July 1982). "Pharmacological analysis of the phencyclidine-like discriminative stimulus properties of narcotic derivatives in rats". The Journal of Pharmacology and Experimental Therapeutics. 222 (1): 146–51. PMID7086696.
^Slifer BL, Balster RL, May EL (October 1986). "Reinforcing and phencyclidine-like stimulus properties of enantiomers of metazocine". Pharmacology, Biochemistry, and Behavior. 25 (4): 785–9. doi:10.1016/0091-3057(86)90388-6. PMID3786338. S2CID32126170.
^"Quotas - 2014". Diversion Control Division. U.S. Department of Justice, Drug Enforcement Administration.